Gerresheimer Ag · XETR:GXI
Gerresheimer — Q1 2025 Earnings Presentation
24 slides from Gerresheimer's earnings presentation, Apr 11, 2025
Slide 1: Q1 2025 Results Presentation
Q1 2025 Results Presentation Dietmar Siemssen Dr. Bernd Metzner
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Q1 2025 Overview
Q1 2025 Overview Dietmar Siemssen (CEO)
Slide 4: Leap forward to a new level - from 2bn revenues in 2024 towards ~2.5bn in 2025
Leap forward to a new level - from 2bn revenues in 2024 towards a level of ~2.5bn in 2025 and adjusted EBITDA margin of ~22% Significantly strengthened position as leading system & solution provider for the pharma & biotech industry Laying the foundation for sustainable profitable growth of 8-10% in
Slide 5: Q1 2025 – Gerresheimer Group Plays in a New League
Q1 2025 – Gerresheimer Group Plays in a New League Leap forward in reported revenue and adjusted EBITDA Growth Revenues Adj. EBITDA (in EURm) (in EURm) Growth yoy: Growth yoy: +11.6% +13.1% 91 520 81 466 Q1 2024 Q1 2025 Q1 2024 Q1 2025 5 11-Apr-2025 Gerresheimer AG - Q1 2025 Results Presentation
Slide 6: Q1 2025 – Growth in absolute terms
Q1 2025 – Growth in absolute terms Organic growth based on prior year’s pro forma figures to resume in Q2 YoY growth − First quarter including − Strong order intake in Q1 Reported Organic Bormioli Pharma laying the foundation for − Phasing impact in coming quarters Revenue +11.6% -6.5% syringes with
Slide 7: Integrate Execute Excel
Leveraging on Unique Business Opportunities to Drive Long-Term Growth Key priorities in FY 2025 — Integrate Bormioli Pharma to enhance product portfolio and seize opportunities for new integrated high-value solutions Integrate — Execute on our growth projects | Ramp-up of Production | Start of contr
Slide 8: Contributions to profitable growth in 2025
Contributions to profitable growth in 2025 Return to operations, ramp-ups and continuous shift to high value products Lohr | Moulded Glass Pharma, F&B Morganton | Vials Skopje | Medical devices Peachtree | Medical devices Bünde | Syringes Querétaro | RTF vials 8 11-Apr-2025 Gerresheimer AG - Q1 2025
Slide 9: Continuous Market Shift Towards Ready-to-fill Solutions
Continuous Market Shift Towards Ready-to-fill Solutions EZ-fill Smart as the next generation platform for RTF vials Shift from bulk to RTF Vials in ~20 years c. 13bn pcs | RTF vials Reduced TCO Improved Sustainability Average Cost reduction -43% CO2e compared to 2034: ~20%-50% Bulk (actual) 20% Bulk
Slide 10: Financial Performance Q1 2025
Financial Performance Q1 2025 Dr. Bernd Metzner (CFO)
Slide 11: Q1 2025 – Slow Start with Growth to Resume in Q2
Q1 2025 – Slow Start with Growth to Resume in Q2 Operational view on KPIs in Q1 2025 FY 2024 figures Revenues1 on pro forma basis Adj. EBITDA1 Adj. EPS (in EURm) (in EURm) (in EUR) Organic growth yoy: Organic growth yoy: Currency-neutral growth yoy: -6.5% -9.3% -36.6% 553 0.65 520 99 92 0.46 Q1 2024
Slide 12: Q1 2025 – Slow/Moderate Start with Growth to Resume in Q2
Q1 2025 – Slow/Moderate Start with Growth to Resume in Q2 Operational view on KPIs in Q1 2025 by division Organic yoy In EURm & margin Revenues1 Adj. EBITDA1 -3.3% -11.4% Phasing Impact in Syringes 71 304 295 63 ▪ Organic revenue decline due to phasing within the syringes business; P&D 23.5% 21.5% m
Slide 13: Moulded Glass Powerhouse – Capex Projects Underway
Moulded Glass Powerhouse – Capex Projects Underway Q1 2025 in detail EURm Q1 20241 Q1 2025 Organic YoY% Revenue 173 159 -8.1% Adj. EBITDA margin ~18% ~20% -- Net capex ~€25m ~€45m -- Q1 2025 revenue split by customer industries Cosmetics Food & Beverages Pharma 1 Q1 2024 pro forma figures 13 11-Apr-
Slide 14: Reconciliation Q1 2025
Reconciliation Q1 2025 Reported and adjusted financials Q1 2025 Q1 2024 Org. growth YoY In EURm Reported Adjustment Adjusted Adjusted Adjusted Revenues 520.1 520.1 466.1 -6.5% EBITDA 82.0 9.5 91.5 80.9 -9.3% Depreciation & Amortization -66.9 17.1 -49.8 -36.8 EBIT 15.1 26.6 41.7 44.1 Financial Result
Slide 15: Q1 2025 – Free Cash Flow Development
Q1 2025 – Free Cash Flow Development Cash flow and net financial debt In EURm Q1 2025 Q1 2024 Adjusted EBITDA 91.5 80.9 Adjustments -9.5 -2.6 EBITDA 82.0 78.3 Change in net working capital -62.5 -24.3 Net interest paid -7.5 -6.2 Net taxes paid -6.6 -6.2 Other -33.2 -14.3 Cash flow from operating act
Slide 16: Financing
Financing Net financial debt & adjusted EBITDA leverage Net Financial Debt Maturity Profile (ProForma incl. Bormioli Bridge) in EURm In EURm Q1 2025 Q1 2024 849 Revolving credit facilities1 62 230 7644 Bridge loan 774 n.a. Promissory loans 1,208 792 774 Local borrowings2 37 33 339 Cash + cash equiva
Slide 17: Outlook
Outlook Dietmar Siemssen (CEO)
Slide 18: Organic Growth Drivers in Q2
Organic Growth Drivers in Q2 Key growth drivers Plastics & Devices Primary Strong Order Packaging Glass Book Organic Growth in Q2 25 Growth in Tubular Glass, Strength in orders firmly firmly backed by solid specifically for HVS backing Year-on-Year growth in syringes and supported by robust revenue
Slide 19: Guidance Gerresheimer Group including Bormioli
Guidance Gerresheimer Group including Bormioli FY 2025 and Mid-Term Guidance (organic; group level) Revenue Adj. EPS Adjusted EBITDA Growth Growth 3-5% ~22% HSD% FY 2025 Growth Margin Growth2,3 8 to 10% 23-25% ≥ 10% Mid-term Growth Growth Margin CAGR CAGR 1 ProForma 2024 figures: Revenues EUR 2.4bn,
Slide 20: Appendix
gerresheimer
Slide 21: Financial Calendar
Financial Calendar Publication 3rd Quarter 2025 Results Publication 2nd Quarter 2025 Results Annual General Meeting 2025 October 10th, 2025 July 10th, 2025 June 5th, 2025 21 11-Apr-2025 Gerresheimer AG - Q1 2025 Results Presentation
Slide 22: Q1 2025 – Revenue & Organic Growth Reconciliation
Q1 2025 – Revenue & Organic Growth Reconciliation in EURm organic growth -6.5% 555.9 -10.0 -3.3% -25.8 519.8 520.1 0.1 -0.4 0.3 87.0 -10.2% 466.1 2.8 Revenue FX Bormioli Revenue Q1 P&D PPG GAT HQ, Cons. Revenue Q1 FX Revenue Q1 2024 2024 (Pro 2025 (organic) Q1 2025 Forma; organic) 22 11-Apr-2025 Ger
Slide 23: Q1 2025 – Adj. EBITDA & Organic Growth Reconciliation
Q1 2025 – Adj. EBITDA & Organic Growth Reconciliation in EURm organic growth margin -9.3% 17.8 100.8 -8.2 18.1% 91.5 91.4 0.1 -2.5 0.6 0.7 -11.4% 2.0 -5.8% 17.6% 80.9 Adj. EBITDA FX Bormioli Adj. EBITDA Q1 P&D PPG GAT HQ, Cons. Adj. EBITDA Q1 FX Adj. EBITDA Q1 2024 2024 (Pro 2025 (organic) Q1 2025 F
Slide 24: innovating for a better life
innovating for a better life